ArticleContemporary clinical trials communications2025
Therapeutic Yoga: A feasible complementary approach for glycemic control in individuals with impaired fasting glucose and elevated HbA1c.
Article in Contemporary clinical trials communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Impaired Fasting Glucose (IFG) with elevated glycated hemoglobin (HbA1c) is a key precursor to type 2 diabetes mellitus (T2DM). Although asymptomatic, IFG significantly raises the risk of developing T2DM and cardiovascular complications, emphasizing the need for early intervention. The Therapeutic Yoga Module (TYM) was designed to offer a feasible and effective remedy for improving glycemic control. Methods: The TYM was designed by combining different yoga practices including asanas, pranayama, relaxation, and dhyana. After validating the module, a feasibility study was carried out on 12 individuals. Subsequently, the preliminary impact was assessed on 29 individuals (intervention group = 14 and control group = 15) with IFG. The study evaluated practicality, participant acceptance, and changes in Fasting Blood Glucose (FBG) and HbA1c levels over 12 weeks. Results: The TYM achieved a content validity index (CVI) of 0.75, with 15 out of 20 practices deemed effective by the expert panel. The Intra-Class Correlation (ICC) coefficient of 0.864 indicated strong reliability. Feasibility testing revealed high participant acceptance, with an average attendance rate of 84.9 %. The intervention group showed significant improvements in FBG (from 108.79 mg/dL to 91.00 mg/dL, P < 0.001) and HbA1c (from 6.00 % to 5.73 %, P < 0.001), compared to the control group, which had more modest improvements. The analysis of covariance (ANCOVA) analysis confirmed that these improvements were primarily attributable to TYM. Conclusion: Preliminary findings suggest that TYM may be a promising complementary intervention for individuals with IFG or at risk of T2DM. Trial registration: Clinical Trials Registry - India (CTRI); Registration number: CTRI/2022/04/042307; Registration Date: April 29, 2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.